AI Article Synopsis
Article Abstract
Introduction: Although the expanding body of research has established firm evidence for the value of some biochemical markers in patients with cardiovascular disease, it has also deluged the clinical and research communities with candidate biomarkers, but very few of them are likely to survive the test of time as useful clinical tool.
Biochemical Markers In Acute Coronary Syndromes: Acute coronary syndrome refers to a constellation of clinical symptoms caused by acute myocardial ischemia. Guidelines for utilization of biochemical markers in acute coronary syndromes are involved in recommendations for use of biomarkers in the initial evaluation of patients with nontraumatic chest symptoms, for diagnosis of myocardial infarction, as well as recommendations for early risk stratification of subsequent death and/or recurrent ischemic event. So, in acute coronary syndromes these biochemical markers are applied: of myocardial necrosis, of cardiac injury, of inflammation, of ischemia and of ventricular wall stress.
Biochemical Markers In Stable Atherosclerotic Disease: When coronary heart disease is concerned, the central place in froreseeing the appearance and development of this disease, is given to risk factors, among them which is a great number of biomarkers. According to all guidelines for cardiovascular disease prevention, lipid parameters represent strong predictors of atherogenesis and coronary heart disease.
Conclusion: The consistent conjunction with atherosclerosis is also mainifested by circulating markers of inflammation. In spite of lack of evidence on measuring the C-reactive protein in a wide population, the guidelines for its application in diagnostics and therapy of coronary heart disease have been developed. In emerging risk factor group there are: homocysteine, prothrombogenic and genetic factors. New potential markers of atherosclerosis include adipocytokines, markers of endothelial function, immunological markers, as well as markers of hepatic and renal dysfunction.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Acute Coronary Syndrome in Brazil: Registration of Predisposing Factors and Population Profile in a National Public Reference Cardiological Institute.
Arq Bras Cardiol
January 2025
Instituto Dante Pazzanese de Cardiologia, São Paulo, SP - Brasil.
Background: Acute coronary syndrome (ACS) is one of the leading causes of mortality worldwide. Knowing the predisposing factors is essential for preventing it.
Objectives: To describe the etiological and epidemiological characteristics of the population with ACS admitted to an emergency room in the State of São Paulo.
Air quality and the risk of acute atrial fibrillation (EP-PARTICLES study): A nationwide study in Poland.
Eur J Prev Cardiol
January 2025
Department of Invasive Cardiology, Medical University of Bialystok, Bialystok, Poland.
Aim: Air pollution remains the single largest environmental health risk factor, while atrial fibrillation (AF) is the most prevalent arrhythmia globally. The study aimed to investigate the relationship between short-term exposure to air pollution and acute AF admissions.
Methods: Individual data on AF hospitalization in the years 2011-2020 were collected from the National Health Fund in Poland (ICD-10: I48.
The prognostic value of global longitudinal strain in patients with myocardial infarction and preserved ejection fraction - a prespecified substudy of the REDUCE-AMI trial.
Eur Heart J Cardiovasc Imaging
January 2025
Department of Clinical Science and Education, Division of Cardiology, Karolinska Institutet, Södersjukhuset, Stockholm, Sweden.
Aims: The REDUCE-AMI trial showed that beta-blockers in patients with preserved left ventricular ejection fraction (LVEF) after acute myocardial infarction (AMI) had no effect on mortality or cardiovascular outcomes. The aim of this substudy was to evaluate whether global longitudinal strain (GLS) is a better prognostic marker than LVEF, and if beta-blockers have a beneficial effect in patients with decreased GLS.
Methods And Results: REDUCE-AMI was a registry-based randomized clinical trial.
Cardiomeds, an mHealth App for Self-Management to Support Swiss Patients With Heart Failure: 2-Stage Mixed Methods Usability Study.
JMIR Form Res
January 2025
Department of Computer Science, University Hospital of Geneva, Geneva, Switzerland.
Background: Mobile health apps have shown promising results in improving self-management of several chronic diseases in patients. We have developed a mobile health app (Cardiomeds) dedicated to patients with heart failure (HF). This app includes an interactive medication list; daily self-monitoring of symptoms, weight, blood pressure, and heart rate; and educational information on HF delivered through various formats.
View Article and Find Full Text PDFImpact of sodium-glucose cotransporter inhibitors in acute coronary syndrome patients on endothelial function and atherosclerosis related-biomarkers: ATH-SGLT2i pilot study.
Medicine (Baltimore)
November 2024
Department of Cardiology, Rabta Teaching Hospital, University of Medicine Tunis, Tunis, Tunisia.
Little is known about the effects of sodium-glucose co-transporter 2 inhibitors (SGLT2i) on atherosclerosis. We aimed to determine if a 90-day intake of Dapagliflozin could improve atherosclerosis biomarkers (namely endothelial function assessed by flow-mediated dilatation [FMD] and carotid intima-media thickness [CIMT]) in diabetic and non-diabetic acute coronary syndrome (ACS) patients when initiated in the early in-hospital phase. ATH-SGLT2i was a prospective, single-center, observational trial that included 113 SGLT2i naive patients who were admitted for ACS and who were prescribed Dapagliflozin at a fixed dose of 10 mg during their hospital stay for either type 2 diabetes or for heart failure.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!